Polycystic Ovary Syndrome (PCOS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Polycystic Ovary Syndrome (PCOS) Market Outlook

Thelansis’s “Polycystic Ovary Syndrome (PCOS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycystic Ovary Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Polycystic Ovary Syndrome (PCOS) Overview

Polycystic Ovary Syndrome (PCOS) is a prevalent metabolic disorder characterized by hormonal imbalances in women of reproductive age (between 12 and 51 years). It is associated with elevated levels of male hormones, leading to irregular menstrual cycles, ovulation difficulties, and potential challenges with conception. Additionally, PCOS can manifest as abnormal hair growth on the body and face and may have long-term implications, such as an increased risk of heart disease and diabetes. The etiology of PCOS remains incompletely understood; nevertheless, several significant factors have been identified, including:

1. Excessive Insulin Production: Elevated insulin levels may stimulate the production of androgens, normally present in lower quantities in females, resulting in ovulation problems.
2. Excessive Androgen Production: The ovaries produce abnormally high levels of androgen hormones, leading to acne and hirsutism (excessive hair growth on the face and body).
3. Low-Grade Inflammation: Recent studies indicate that females with PCOS experience low-grade inflammation, contributing to increased androgen production and potential cardiovascular issues.
4. Heredity: There is evidence of a genetic correlation among women affected by PCOS.

Common signs and symptoms of PCOS in females include irregular menstruation (oligomenorrhea), skipped or absent menstruation (amenorrhea), heavy menstrual bleeding (menorrhagia), excessive hair growth on various body areas, acne, weight gain, hair loss, and skin darkening in specific regions. Only a few agents have received approval from the U.S. Food and Drug Administration specifically for treating polycystic ovary syndrome. Several agents are contraindicated during pregnancy. Insulin-sensitizing agents are recommended for most women with PCOS as they positively affect insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Among these agents, metformin has the most extensive data supporting its effectiveness. Additionally, rosiglitazone and pioglitazone have effectively reduced hirsutism and insulin resistance. Metformin and clomiphene, combined, are considered first-line treatments for inducing ovulation. Furthermore, insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine may be utilized to manage hirsutism in affected patients.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: